Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 Neurovascular Support Catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) Annual Meeting. The data—presented publicly for the first time —demonstrates strong performance compared to other super-bore catheters in key performance metrics such as trackability, atraumatic design and overall physician-rated experience.
Collected from 105 procedures across 37 U.S. centers and 41 physicians, the preference test revealed:
- 95% of physicians reported that SOFIA™ 88 catheter reliably reached the target location—even in anatomically challenging cases, with 59% of procedures in ICA-T or beyond
- 86% of physicians rated the SOFIA™ 88 catheter as “Better” or “Much Better” than alternatives overall
- Physician data included: SOFIA™ 88 catheter outperformed the ZOOM 88 catheter in 94% of cases and the HiPoint 88 catheter in 79%
“These real-world results further validate SOFIA™ 88 catheter’s position as a leading super-bore support catheter,” said Carsten Schroeder, President and CEO of Terumo Neuro. “This new dataset reinforces what we’ve heard consistently from physicians: the SOFIA™ 88 catheter delivers reliable performance where it matters most. We are proud to see the catheter outperform other large-bore devices in real-world settings—and even more proud that this innovation was shaped through close physician partnership. It reflects our long-standing commitment to delivering meaningful neurovascular advancements rooted in evidence, experience, and collaboration.”
The SOFIA™ 88 Neurovascular Support Catheter was commercially launched in the U.S. on May 13, 2025, as the latest addition to Terumo Neuro’s global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the SOFIA™ 88 catheter is designed to optimize physician control and integration into a variety of aspiration and combination strategies.
The physician preference data unveiled at SNIS builds on results from the SOFAST registry, which demonstrated the safety and efficacy of the SOFIA™ Flow Plus 6F catheter as a frontline aspiration device.
The SOFIA™ 88 catheter is compatible with the SOFIA™ Flow Plus 6F Aspiration Catheter and is part of Terumo Neuro’s fully integrated stroke solution, including:
- ERIC™ Retrieval Device – For thrombus control and procedural versatility
- BOBBY™ Balloon Guide Catheter – Offering reliable flow arrest with next-gen balloon technology
- WEDGE™ and HEADWAY™ Microcatheters – Designed for navigation support and access efficiency
- TRAXCESS™ Guidewires – Soft-tip wires built for challenging anatomies
